About TYME
TYME is an emerging biotechnology company focused on exploring novel therapeutic approaches to target cancer’s unique metabolism. To date, oral SM-88, our lead Cancer Metabolism-Based Compound (CMBTs™) has demonstrated clinical responses in 15 different cancer types across four separate studies.
Oral SM-88 is being evaluated as a potential therapy for patients in prostate, pancreatic, and sarcomas. TYME is now enrolling patients in the TYME-88-Panc pivotal study for patients with third-line pancreatic cancer and HopES Sarcoma study. Learn more at TYMEtrials.com...
More Info Less Info